KDR and neoplasm: For this purpose, we performed a time evolution study in an experimental colon carcinoma model by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to assess tumour vascular responses during 2 weeks of treatment with SU6668, a small molecule inhibitor of the angiogenic receptor tyrosine kinases, VEGFR-2 (Flk-1/KDR), PDGFR-β and FGFR1.